Follow us


Our regular patent and pharma update aims to keep you informed of recent developments in United Kingdom and European law relating to patents and the pharmaceutical industry.

A summary of the key themes are below.

UPC update

UPC commencement postponed – Preparatory Committee announces that 1 December 2017 start date cannot be maintained


 

UK Court takes tough stance on party unwilling to take worldwide licence on FRAND terms

The UK High Court has handed down its first decision determining FRAND royalties, and provided clear guidance as to the rights and obligations of parties to licensing negotiations and litigation relating to standard essential patents


 

Further consideration of SPCs

Four recent cases have dealt with the requirements to obtain an SPC. In three of these cases, Arnold J has considered the meaning of Article 3(a) of the SPC Regulation which requires that for an SPC to be granted, the relevant "product" must be "protected by a basic patent". In the fourth case, Arnold J considered the meaning of Article 3(d) of the SPC Regulation and whether an SPC can be granted for a new and inventive formulation of an old active ingredient


 

Court of Appeal judgment on employee compensation - Shanks v Unilever

The Court of Appeal has considered the meaning of "outstanding benefit" in relation to a claim for employee compensation under s.40 of the Patents Act 1977


 

How to construe a patent – recent developments

A string of recent English court decisions have grappled with issues of patent construction considering, in particular, how a notional skilled person would interpret a divisional patent or the impact of a reference in a patent to comparative examples of prior art


 

Prior art in the internet age

Two recent cases (one in the EPO and the other in the UK Court of Appeal ) deal with establishing the existence of prior art on the internet


 

"We'll sue you if you don't stop …" more flexibility to threaten IP proceedings under the new Unjustified Threats legislation in the UK

The new Intellectual Property (Unjustified Threats) Act 2017 confirms what can be a threat whilst providing for "permitted communications" or communications for "permitted purposes" which cannot be threats


 

Read the full update

Key contacts

Sebastian Moore photo

Sebastian Moore

Partner and Head of Intellectual Property, UK, London and Milan

Sebastian Moore
Jonathan Turnbull photo

Jonathan Turnbull

Partner, London

Jonathan Turnbull
Monika Klajn photo

Monika Klajn

Senior Associate, London

Monika Klajn
Rachel Montagnon photo

Rachel Montagnon

Professional Support Consultant, London

Rachel Montagnon

Stay in the know

We’ll send you the latest insights and briefings tailored to your needs

London Intellectual Property Patents Pharmaceuticals and Healthcare Pharmaceuticals Sebastian Moore Jonathan Turnbull Monika Klajn Rachel Montagnon